Scientists tracking ‘interstellar' object that has come to us from another solar system
The object, a celestial body from another star system, was discovered on Tuesday by the University of Hawaii's Asteroid Terrestrial-impact Last Alert System, or ATLAS, team. At this point, it remains unclear what the object may be or look like as it moves near Jupiter.
Now, scientists are checking to confirm their findings.
'ESA's Planetary Defenders are observing the object, provisionally known as #A11pl3Z, right now using telescopes around the world,' the European Space Agency said in a social media post on Wednesday. The National Aeronautics and Space Administration told The Associated Press that it is monitoring the situation.
David Rankin, of the University of Arizona's Catalina Sky Survey, said in posts on BlueSky that follow-up observations were made not long after the discovery. A precovery — observations from archival images in which the object was not originally discovered — from CalTech's Zwicky Transient Facility hinted at the presence of an interstellar object.
'After a few more precovery observations, and follow-ups, it became clear this object is on a hyperbolic trajectory through the solar system,' Rankin wrote.
Since then, new observations have been 'rolling in,' helping astronomers to better determine its orbit.
Rankin noted that the first known interstellar object to visit our solar system was 'Oumuamua, which was spotted in 2017.
Up to one-quarter mile-long and 10 times as long as it is wide, its resembles a rocky cigar with a reddish hue. Its aspect ratio, which is greater than that of any asteroid or comet observed in our solar system to date, even led to speculation that it could be an alien spacecraft.
Observations then suggested that it had been wandering through our Milky Way galaxy for hundreds of millions of years before its encounter with our star system, according to NASA.
The second known object was Comet 2I/Borisov, found in 2019. It is the first confirmed interstellar comet, and was later captured by the Hubble Space Telescope.
Scientists believe that many more such objects regularly pass by the Earth, with a number of them flying relatively near to us each year. However, many of them go undetected because they are hard to spot and it is difficult to know for sure where they have come from.
Researchers hope to eventually learn more about them and even use them as evidence for distant star systems and planets.
They also hope to find more of them in the years to come, thanks to new and more powerful telescopes, such as the recently switched-on Vera C Rubin Observatory.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Learn About: NASA's Lucy Spacecraft Flyby With Asteroid Donaldjohanson
Learn more about the Lucy mission "fly past 52246 Donaldjohanson -NASA's Goddard Space Flight Center. Credit: NASA's Goddard Space Flight Center Dan Gallagher: Producer/Narrator Adriana Manrique Gutierrez: Animator Kel Elkins: Animator Johathan North: Animator Michael Lentz: Animator/Art Director Walt Feimer: Animation Lead Nancy Jones: Public Affairs Katherine Kretke: Public Affairs Universal Production Music: 'Nico's Journey' by Nicholas Smith [PRS]; 'Knowing Half the Future' and 'Temporal Timings' by Lee John Gretton [PRS]; 'Poly Propulsion' by Alfie Solo [PRS]
Yahoo
20 minutes ago
- Yahoo
Thermo Fisher's NGS Assay Receives FDA Approval as a Companion Diagnostic for ZEGFROVY and for Tumor Profiling
Oncomine Dx Express Test on the Ion Torrent Genexus Dx Integrated Sequencer generates results in as little as 24 hours to support timely therapy decisions CARLSBAD, Calif., July 03, 2025--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the U.S. Food and Drug Administration (FDA) has approved the Oncomine™ Dx Express Test on the Ion Torrent™ Genexus™ Dx Integrated Sequencer as an in vitro diagnostic (IVD) assay for use as a companion diagnostic (CDx) for Dizal's ZEGFROVY® (sunvozertinib) and in tumor profiling. This approval brings rapid next-generation sequencing (NGS) to decentralized clinical settings closer to where patients receive care. With the ability to deliver essential genomic insights in as little as 24 hours*, this approval helps advance the accessibility of precision oncology tools and enables more timely decision making. A patient's tumor profile has the potential to guide precision oncology care. However, delays in obtaining results can hinder clinicians' ability to make informed decisions, potentially causing patients to miss out on targeted therapies, which can impact treatment efficacy and patient outcomes. Furthermore, a significant number of patients miss out on targeted therapies due to inefficiencies or lack of access to testing, highlighting the critical role of timely genomic profiling. The Oncomine Dx Express Test was designed to simplify the NGS workflow and connect patients everywhere to precision oncology. Now with the Oncomine Dx Express Test on the Ion Torrent Genexus Dx Integrated Sequencer, laboratories across a variety of clinical settings can deliver rapid genomic profiling with exceptional accuracy and ease, helping to ensure patients can benefit from the latest advancements in precision oncology. The Oncomine Dx Express Test is intended for use as a companion diagnostic for ZEGFROVY (sunvozertinib), a targeted therapy from Dizal, to identify patients with non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations. In addition, the test has been approved for tumor profiling in solid tumors and detects cancer mutations with evidence of clinical significance and potential clinical significance across 46 genes. Accelerating informed precision oncology care The Genexus Dx Integrated Sequencer automates the NGS workflow — from sample preparation to data analysis and reporting — making the technology accessible to more laboratories, including those that are smaller and without previous NGS expertise. It also enables laboratories to generate timely CDx results as well as tumor profiling reports in as little as 24 hours, helping accelerate insights and access to precision oncology. "NGS has been instrumental in advancing precision oncology, but these insights often aren't available early enough to inform real-world care," said Kathy Davy, president of Clinical Next-Generation Sequencing at Thermo Fisher Scientific. "With our rapid NGS solutions, we aim to deliver timely results to clinicians and their patients prior to the initiation of treatment. We've been leading companion diagnostics in collaboration with our pharma partners for a decade, and this approval signifies the next step in our journey bringing rapid, decentralized NGS CDx to drug development. We are proud of our collaboration with Dizal to bring ZEGFROVY to the US market." Biodesix, one of Thermo Fisher's collaborators in the validation of Oncomine Dx Express Test on the Genexus Dx Integrated Sequencer, will be the first lab to launch testing services. "The Biodesix team is excited at the prospect of using the newly FDA approved Genexus Dx Integrated Sequencer for clinical testing using the Oncomine Dx Express test and for supporting our biopharma client projects," said Gary Pestano, Ph.D., chief development officer at Biodesix. "Automation of the systems for nucleic acid purification, library preparation, sequencing and report generation has the potential to significantly improve our NGS laboratory workflows by reducing hands-on time and by delivering rapid turnaround times - from sample receipt to results." ZEGFROVY (sunvozertinib) CDx approval ZEGFROVY, developed by Dizal, was granted FDA accelerated approval following Breakthrough Therapy designation and Priority Review for the treatment of NSCLC patients with EGFR exon 20 insertion mutations. With the approval of the Oncomine Dx Express Test on the Genexus Dx Integrated Sequencer as a companion diagnostic for this therapy, clinicians can now quickly identify eligible patients – supporting earlier intervention and expanding access to targeted therapy. "ZEGFROVY is a highly effective and currently the only approved EGFR TKI targeting EGFR exon 20 insertion mutations. The approval of ZEGFROVY will have a significant impact on platinum-pretreated patients with NSCLC harboring EGFR exon 20 insertion mutations, a difficult-to-treat lung cancer subtype," said Susan Chen, senior vice president, head of clinical operation at Dizal. "Today's FDA approval of the Oncomine Dx Express Test offers access to ZEGFROVY through decentralized companion diagnostic testing. The ability to match patients to our therapy quickly and accurately, regardless of mutation location, can improve outcomes for this patient population." To learn more about today's approval, please visit * Timing varies by number of samples and type of run. About Thermo Fisher ScientificThermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit View source version on Contacts Media Contact Information:Jen CarrollPhone: (760) 583-8898Email: Jessika ParryPhone: (419) 266-4016Email: jparry@
Yahoo
20 minutes ago
- Yahoo
Large Unidentified Object Detected Entering Our Solar System
In 2017, 'Oumuamua stunned scientists as the interstellar object entered and then exited the solar system, something previously unprecedented in the world of astronomy. In 2019, the comet Borisov was deemed the second interstellar object to enter our solar system. However, in 2022, another object was found to have previously come into our solar system and struck earth, without notice, in 2014. These three are the only known interstellar objects to have entered our solar system in recorded human history. But now a fourth and much larger object has been spotted entering the solar system, and the scientific community is rushing to study what, exactly, this thing is. While these findings are subject to change as more data becomes available, the object, dubbed A11pl3Z, is quite large. According to a Medium article by Harvard astronomer Avi Loeb, A11pl3X's H-magnitude of 12, previously listed by NASA, suggests a diameter of about 20 kilometers. Recent adjustments to the H-magnitude, now listed at 13.6, indicate that it may be even larger. Another interpretation of the data, according to Loeb, could suggest that A11pl3Z is smaller than these estimates, but a plume of gas and dust are creating the illusion of a much larger object. This simulation of A11pl3Z's trajectory, created by amateur astronomer Tony Dunn, shows its likely path in relation to the sun and planets: According to Dunn's projected trajectory, the object is expected to pass quite far from Earth but inside Mars' orbit, measuring 2.4 times as far from Earth as Earth's distance from the Sun when it reaches its closest point on Dec. 17 of this year. Marshall Eubanks, physicist and co-founder of Space Initiatives, commented on the object's speed to the The Minor Planet Mailing List, writing 'next April (2026) it will have a velocity relative to Earth of ~ 90 km/s. That should set a record.' Eubanks added that the object may be visible from the Mars Reconnaissance Orbiter when it passes 'relatively close to Mars' in October. The Minor Planet Mailing List hosts public discourse as a service to the astronomical community, and is, according to its website, 'populated with many of the world's best amateur astronomers as well as many professional astronomers involved in all facets of asteroid and comet research.' Large Unidentified Object Detected Entering Our Solar System first appeared on Men's Journal on Jul 2, 2025